228 patents
Page 4 of 12
Utility
Expanded T Cell Assay
28 Jul 22
Assays for assessing the therapeutic efficacy of vaccines, including personalized cancer vaccines are provided.
Kristen Hopson
Filed: 29 May 20
Utility
Heterologous UTR sequences for enhanced mRNA expression
19 Jul 22
mRNAs containing an exogenous open reading frame (ORF) flanked by a 5′ untranslated region (UTR) and a 3′ UTR is provided, wherein the 5′ and 3′ UTRs are derived from a naturally abundant mRNA in a tissue.
David H. Burkhardt, Romesh R. Subramanian, Christian Cobaugh
Filed: 9 Dec 16
Utility
RNA affinity purification
12 Jul 22
Provided herein, in some embodiments, are methods of purifying a nucleic acid preparation.
Edward J. Miracco
Filed: 13 Dec 17
Utility
Ribonucleic acid purification
5 Jul 22
Disclosed herein are methods for purifying RNA comprising poly A.
William Joseph Issa, John Grant Aunins, Stephane Bancel
Filed: 13 Mar 14
Utility
Respiratory Virus Nucleic Acid Vaccines
30 Jun 22
Provided herein, in some embodiments, are vaccines (and vaccination methods) that include a ribonucleic acid (RNA) polynucleotide encoding a human metapneumovirus (hMPV) F protein and a RNA polynucleotide encoding a human parainfluenza virus 3 (hPIV3) F protein.
Giuseppe Ciaramella, Sunny Himansu
Filed: 26 Jul 21
Utility
Nucleic Acid Vaccines
23 Jun 22
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines (NAVs) comprising polynucleotide molecules encoding one or more antigens.
Giuseppe Ciaramella, Axel Bouchon, Eric Yi-Chun Huang
Filed: 28 Feb 22
Utility
CHIKV RNA vaccines
21 Jun 22
Aspects of the disclosure relate to nucleic acid vaccines.
Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir
Filed: 10 Jun 20
Utility
Mrna Based Enzyme Replacement Therapy Combined with a Pharmacological Chaperone for the Treatment of Lysosomal Storage Disorders
16 Jun 22
This disclosure relates to treatment of lysosomal storage disorders, such as Fabry disease or Gaucher disease, with a combination treatment containing (i) an mRNA encoding a lysosomal enzyme deficient in the lysosomal storage disorder, and (ii) a compound that is a glucosylceramide synthase inhibitor or a pharmacological chaperone of the lysosomal enzyme. mRNAs for use in the invention, when administered in vivo, encode the enzyme that is deficient in the lysosomal storage disorder, functional fragments thereof (e.g., those comprising the catalytic domain), or fusion proteins containing the enzyme that is deficient in the lysosomal storage disorder. mRNA therapies can be used to increase and/or restore deficient levels of a lysosomal enzyme's expression and/or activity in subjects.
John Mendlein
Filed: 22 Jul 19
Utility
Zika Virus Rna Vaccines
9 Jun 22
Provided herein, in some embodiments, are Zika virus RNA vaccines and methods of producing an antigen-specific immune response in a subject.
Giuseppe Ciaramella, Sunny Himansu
Filed: 19 Nov 21
Utility
HMPV/hPIV3 mRNA vaccine composition
7 Jun 22
Provided herein are vaccine composition comprising a chemically-modified messenger ribonucleic acid (mRNA) encoding a hMPV fusion (F) glycoprotein and a chemically-modified mRNA encoding a hPIV3 F glycoprotein formulated in a cationic lipid nanoparticle formulation, and related method for inducing an antigen-specific immune response.
Lori Panther, Christine Shaw, Igor Smolenov, Michael Watson, Tal Zaks
Filed: 11 Feb 20
Utility
Combinations of mRNAs encoding immune modulating polypeptides and uses thereof
31 May 22
The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).
Joshua P. Frederick, Ailin Bai, Vladimir Presnyak, Stephen G. Hoge, Kerry Benenato, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe, Susannah Hewitt
Filed: 21 Jun 21
Utility
Fed-batch In Vitro Transcription Process
12 May 22
The present disclosure provides methods of in vitro transcribing a ribonucleic acid (RNA) of interest.
Joseph Elich, Amy E. Rabideau, Michael Shamashkin, Rosalie Philpot, Brian Fritz, Peter Wojciechowski
Filed: 11 Mar 20
Utility
Rna Cancer Vaccines
28 Apr 22
The present application is related to a method of treating a cancer by administering to a human subject multiple doses of a mRNA cancer vaccine formulated as a lipid nanoparticle wherein the cancer vaccine comprises one or more mRNAs each having one or more open reading frames encoding 3-50 peptide epitopes, and wherein each of the peptide epitopes are portions of personalized cancer antigens or portions of cancer hotspot antigens.
Ted Ashburn, Kristen Hopson, Karen Keating, Joseph Senn, Christine Swenson, Benjamin Breton, Shan Zhong, Maija Garnaas
Filed: 7 Nov 19
Utility
Vortex Mixers and Associated Methods, Systems, and Apparatuses Thereof
28 Apr 22
A vortex mixer may have a vortex mixing chamber having a first wall, a second wall, and a side wall connecting the first wall and the second wall.
Stephanie KIRBY, Benjamin GELDHOF, Kaelyn VIK, Brie SKINNER
Filed: 31 Jan 20
Utility
Polynucleotides encoding interleukin-12 (IL12) and uses thereof
26 Apr 22
The present disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human interleukin-12 (IL12), functional fragments thereof, and fusion proteins comprising IL12.
Joshua Frederick, Susannah Hewitt, Ailin Bai, Stephen Hoge, Vladimir Presnyak, Iain McFadyen, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe
Filed: 5 May 21
Utility
CorrectedZoonotic Disease Rna Vaccines
21 Apr 22
The disclosure relates to Lassa virus, Nipah virus, and betacoronavirus ribonucleic acid vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
Giuseppe Ciaramella, Sunny Himansu, Vladimir Presnyak, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe
Filed: 22 Jan 21
Utility
Polynucleotides Encoding Very Long-chain Acyl-coa Dehydrogenase for the Treatment of Very Long-chain Acyl-coa Dehydrogenase Deficiency
14 Apr 22
This disclosure relates to mRNA therapy for the treatment of very long-chain specific acyl-CoA dehydrogenase deficiency (VLCADD). mRNAs for use in the invention, when administered in vivo, encode human very long-chain specific acyl-CoA dehydrogenase (VLCAD). mRNA therapies of the disclosure increase and/or restore deficient levels of VLCAD expression and/or activity in subjects. mRNA therapies of the disclosure further decrease abnormal accumulation of acylcarnitine associated with deficient VLCAD activity in subjects.
Vladimir Presnyak, Paolo Martini
Filed: 29 Aug 19
Utility
COMPOSITIONS COMPRISING SYNTHETIC POLYNUCLEOTIDES ENCODING CRISPR RELATED PROTEINS AND SYNTHETIC SGRNAs AND METHODS OF USE
14 Apr 22
The present invention relates to compositions comprising and methods of using synthetic polynucleotides, e.g., modified mRNA, encoding CRISPR related proteins including dCAS9 and synthetic sgRNAs targeting a gene of interest.
Stephen G. HOGE, Eric Yi-Chun HUANG, Tirtha CHAKRABORTY
Filed: 25 May 21
Utility
High Purity Rna Compositions and Methods for Preparation Thereof
31 Mar 22
The invention relates to improved RNA compositions for use in therapeutic applications.
Stephen Hoge, William Issa, Edward J. Miracco, Jennifer Nelson, Amy E. Rabideau, Gabor Butora
Filed: 10 Nov 21
Utility
High Purity Rna Compositions and Methods for Preparation Thereof
31 Mar 22
The invention relates to improved RNA compositions for use in therapeutic applications.
Stephen Hoge, William Issa, Edward J. Miracco, Jennifer Nelson, Amy E. Rabideau, Gabor Butora
Filed: 10 Nov 21